Q BioMed Inc. and Mannin Research Inc. Sign Definitive License Agreement

NEW YORK—Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc., a biotechnology company leading the development of a new class of vascular therapeutics. The drug development program at Mannin is led by Mannin’s chief scientific officer, Dr. Susan E. Quaggin, chief of the Division of Nephrology and director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago. Utilizing a proprietary research platform, this technology is addressing the need for a new class of drugs to treat diseases such as…


Global Contact Lens Forum Brings Leaders Together

  LAS VEGAS—International Vision Expo West once again will host The Global Contact Lens Forum, an exclusive “meeting within a meeting” which brings together many of the most highly respected leaders in the contact lens field to share their expertise. The event combines the latest scientific content with critical business strategies, covering topics from profitability, disease and technology, as well as forecasting the future of the contact lens industry. Endorsed by the British Contact Lens Association (BCLA) and the Contact Lens Society of America (CLSA), the Global Contact Lens Forum will take place on Wednesday, Sept. 16 with six hours…


Main Street Capital Partners With I-deal Optics

Michael Feldman, I-deal Optics CEO and president.​ TROY, Mich.—I-deal Optics, a leading wholesale distributor of high margin eyewear and sunwear, has announced that Main Street Capital Holdings, LLC has partnered with the company. Financial terms of the deal were undisclosed. In its announcement, I-deal said its entire management team remains in place, as owners and their roles within the company will be the same. All inside employees and sales representatives’ positions remained unchanged. Michael Feldman, I-deal Optics CEO and president, said “What a great opportunity for the company to be able to partner with Main Street Capital Holdings. Our vision…


American Board of Optometry Board Certification to be Included on Physician Compare

ST. LOUIS—The Centers for Medicare and Medicaid Services (CMS) announced that the American Board of Optometry (ABO) Board Certification will be added to the Physician Compare website on Medicare.gov. The announcement came as part of a final rule issued by CMS updating payment policies, payment rates and quality provisions for services furnished under the Medicare Physician Fee Schedule (PFS) on or after Jan. 1, 2016. In continuing the move toward public reporting, Certifying Board will be included in provider credentials on Physician Compare, including the addition of the American Board of Optometry as a Certifying Board. ABO is the only…


Allergan to Acquire Glaucoma Treatment Company AqueSys

DUBLIN and ALISO VIEJO, Calif.—Allergan (NYSE: AGN), a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure associated with glaucoma, announced yesterday that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction. Under the terms of the agreement, Allergan will acquire AqueSys for a $300 million upfront payment and regulatory approval and commercialization milestone payments related to AqueSys’ lead development programs, including XEN45. “The acquisition of AqueSys and its XEN45 program builds on Allergan’s deep and long-standing commitment to…